Enoc Granados Centeno

This paper shows leukemia induces neoantigen-specific CD4+ T cells to become regulatory (Tr1) cells, which suppress cytotoxic T cells and promote relapse, and repolarizing these cells to Th1 states eradicates residual disease.

This study compares the effects of nilotinib and dasatinib on anti-leukemia immune responses when combined with PD-L1 blockade, finding that nilotinib synergizes with PD-L1 blockade to prevent relapse while dasatinib does not.